MRI in diagnosis of pathological complete response in breast cancer patients after neoadjuvant chemotherapy

被引:7
|
作者
Li, Yan-Ling [1 ]
Zhang, Xiao-Peng [1 ]
Li, Jie [1 ]
Cao, Kun [1 ]
Cui, Yong [1 ]
Li, Xiao-Ting [1 ]
Sun, Ying-Shi [1 ]
机构
[1] Peking Univ, Canc Hosp & Inst, Dept Radiol, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100871, Peoples R China
基金
中国国家自然科学基金;
关键词
Magnetic resonance imaging; Breast cancer; Neo-adjuvant chemotherapy; Pathological complete response; SURGICAL ADJUVANT BREAST; RESIDUAL DISEASE; PREOPERATIVE CHEMOTHERAPY; INDUCTION CHEMOTHERAPY; TUMOR RESPONSE; ENHANCED MRI; ACCURACY; SIZE; MAMMOGRAPHY; DOCETAXEL;
D O I
10.1016/j.ejrad.2014.11.029
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective: To select effective indicators for diagnosis of pathological complete response (pCR) by MRI and to establish an appropriate diagnostic program to maximize the accuracy of pCR detection by MRI. Materials and methods: Twenty-one pCR patients and 22 non-pCR randomly selected patients receiving neoadjuvant chemotherapy (NAC) and subsequent surgery were recruited for the study. All patients underwent breast MRIs both before and after chemotherapy. Changes in diameter, area and dynamic variables between the first and final MRI were compared between the two groups. Logistic and ROC analysis were performed to select effective indicators for predicting pCR on MRI. Results: Eleven out of 43 patients had no residual enhanced areas on MRI, and the sensitivity and specificity for predicting pCR on MRI under the current criterion was 52.38% and 100%, respectively. Logistic regression analysis revealed that changes in diameter, SIpeak and area were effective in predicting pCR by MRI. The latter two parameters had a greater impact on diagnosis than the diameter change. Two new independent criteria were established to predict pCR on MRI: (1) a reduction of >= 78% in area; and (2) a combination of a reduction of >= 27% in SIpeak and of >= 78% in area on MRI. Both had diagnostic accuracy of 88.37% and criterion 1 had higher sensitivity of 90.48%. However, criterion 2 had perfect specificity of 100%. Conclusion: MRI is an effective means for detecting pCR from non-pCR patients. Changes in area and SIpeak can be used to establish two new independent criteria which perform better in diagnosing pCR on MRI than the current criterion. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:242 / 249
页数:8
相关论文
共 50 条
  • [1] Pathological Complete Response Patients after Neoadjuvant Chemotherapy in Breast Cancer
    Takaoka, Megumi
    Ohsumi, Shozo
    Ikejiri, Haruka
    Shidahara, Tomohiro
    Miyoshi, Yuichiro
    Takahashi, Mina
    Takashima, Seiki
    Aogi, Kenjiro
    [J]. ACTA MEDICA OKAYAMA, 2022, 76 (02) : 105 - 111
  • [2] Characteristics of breast cancer patients with pathological complete response after neoadjuvant chemotherapy
    Kolacinska, Agnieszka
    Blasinska-Morawiec, Maria
    Dowgier-Witczak, Izabela
    Kordek, Radzislaw
    Morawiec, Zbigniew
    [J]. MENOPAUSE REVIEW-PRZEGLAD MENOPAUZALNY, 2010, 9 (05): : 300 - 304
  • [3] Pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy
    Montemurro, Filippo
    Di Cosimo, Serena
    [J]. BREAST, 2014, 23 (05): : 690 - 691
  • [4] Improving pathological complete response in luminal breast cancer after neoadjuvant chemotherapy
    Cudos, Ariadna Gasol
    Murillo, Serafin Morales
    Galindo, Alvaro Rodriguez
    Subirats, Ona Pallise
    Olive, Jordi Mele
    Morales, Carles Canosa
    Villellas, Felip Vilardell
    Guzman, Douglas Rene Sanchez
    Rodriguez, Joel Veas
    [J]. CANCER RESEARCH, 2022, 82 (04)
  • [5] Demographic determinants of pathological complete response after neoadjuvant chemotherapy in breast cancer
    Dharanikota, A.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1482 - S1482
  • [6] Pathological complete response (pCR) after neoadjuvant chemotherapy in luminal breast cancer
    Cordoba Ortega, J. F.
    Gasol Cudos, A.
    Morales Murillo, S.
    Vilardell Villellas, F.
    Siso Raber, C.
    Canosa Morales, C.
    Salud Salvia, A.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S313 - S313
  • [7] Dedicated breast PET to predict pathological complete response after neoadjuvant chemotherapy for breast cancer
    Fujiwara, M.
    Masumoto, N.
    Sasada, S.
    Kadoya, T.
    Okada, M.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [8] Computer-aided classification of MRI for pathological complete response to neoadjuvant chemotherapy in breast cancer
    Yan, Shaolei
    Peng, Haiyong
    Yu, Qiujie
    Chen, Xiaodan
    Liu, Yue
    Zhu, Ye
    Chen, Kaige
    Wang, Ping
    Li, Yujiao
    Zhang, Xiushi
    Meng, Wei
    [J]. FUTURE ONCOLOGY, 2022, 18 (08) : 991 - 1001
  • [9] MRI and Prediction of Pathologic Complete Response in the Breast and Axilla after Neoadjuvant Chemotherapy for Breast Cancer
    Weber, Joseph J.
    Jochelson, Maxine S.
    Eaton, Anne
    Zabor, Emily C.
    Barrio, Andrea V.
    Gemignani, Mary L.
    Pilewskie, Melissa
    Van Zee, Kimberly J.
    Morrow, Monica
    El-Tamer, Mahmoud
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2017, 225 (06) : 740 - 746
  • [10] Prediction of pathological complete response by microRNA in breast cancer patients treated with neoadjuvant chemotherapy
    Shimomura, Akihiko
    Shiino, Sho
    Kawauchi, Junpei
    Takizawa, Satoko
    Ichikawa, Makiko
    Matsuzaki, Juntaro
    Sakamoto, Hiromi
    Kinoshita, Takayuki
    Tamura, Kenji
    Ochiya, Takahiro
    [J]. CANCER SCIENCE, 2018, 109 : 394 - 394